Recombinant Human Antibody (10C12) Fab Fragment is specific to Factor IX, expressed in Chinese Hamster Ovary cells (CHO).
Figure 1 F.IX activation by F.XIa and by the tissue factor:factor VIIa (TF:F.VIIa) complex.
F.IX (400 nM) was incubated with 10C12 (filled symbols) or a control antibody (NTN: anti-neurturin) (open symbols) in HBSA-5 mM CaCl₂. (A) 1 nM F.XIa was added to start the reaction. (B) Relipidated TF:F.VIIa (4 nM:1 nM) (circles) or membraneTF:F.VIIa (150 μg/ml:1nM) (squares) was added to start the reaction. At defined time intervals reaction aliquots were quenched in EDTAethyleneglycol and F.IXa amidolytic activity in each sample was determined after adding F.IXa substrate #299. The inhibition of the rates of F.IXa generation were expressed as fractional rates (vᵢ/vo) ± SD of 4 independent experiments (except for the NTN control in Fig. 1A where n = 3)
Refino, C. J., Himber, J., Burcklen, L., Moran, P., Peek, M., Suggett, S., ... & Kirchhofer, D. (1999). A human antibody that binds to the γ-carboxyglutamic acid domain of factor IX is a potent antithrombotic in vivo. Thrombosis and haemostasis, 82(09), 1188-1195.
Figure 2 Measurement of activated partial thromboplastin time (APTT) and prothrombin time (PT) in plasma of guinea pig and rat.
10C12 was diluted in citrated plasma of guinea pig and rat. After an incubation of 10 min, human relipidated tissue factor (Innovin) or Actin FS were added to start the PT (open symbols) and APTT (filled symbols) reaction, respectively. The effects on clotting were expressed as fold prolongation of control plasma clotting times. Diamonds = guinea pig; circles = rat.
Refino, C. J., Himber, J., Burcklen, L., Moran, P., Peek, M., Suggett, S., ... & Kirchhofer, D. (1999). A human antibody that binds to the γ-carboxyglutamic acid domain of factor IX is a potent antithrombotic in vivo. Thrombosis and haemostasis, 82(09), 1188-1195.
Figure 3 Effects of 10C12 on cyclic flow variations (CFVs) in guinea pig arterial thrombosis model.
10C12 and controls were given by intravenous bolus administration 15 min prior to the initiation of CFVs in the carotid artery. The number of CFVs during a 40 min period was recorded and the thrombosis index calculated as the ratio of CFVs divided by the number of applied pinches. ** p<0.01, *** p <0.001 versus control by Mann-Whitney U-test following determination of significant differences between multiple groups in KruskalWallis test
Refino, C. J., Himber, J., Burcklen, L., Moran, P., Peek, M., Suggett, S., ... & Kirchhofer, D. (1999). A human antibody that binds to the γ-carboxyglutamic acid domain of factor IX is a potent antithrombotic in vivo. Thrombosis and haemostasis, 82(09), 1188-1195.
Figure 4 Blood loss from a standardized puncture wound of rabbit tibias for three consecutive 30-minute periods.
The treatment groups were saline (open bar), 10C12 administered as a single bolus of 30 μg/kg (hatched bar), and heparin administered as a bolus of 100 U/kg followed by a continuous infusion of 1 U · kg⁻¹ · min⁻¹ for 30 minutes (closed bar). N5 per treatment. Times were 0 to 30 minutes (before treatment), 30 to 60 minutes (post-treatment but during the heparin infusion), 60 to 90 minutes (post-treatment but after termination of heparin infusion). *P≤0.05 versus saline control.
Refino, C. J., Jeet, S., DeGuzman, L., Bunting, S., & Kirchhofer, D. (2002). A human antibody that inhibits factor IX/IXa function potently inhibits arterial thrombosis without increasing bleeding. Arteriosclerosis, thrombosis, and vascular biology, 22(3), 517-522.
This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:
• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production
See more details about Hi-Affi™ recombinant antibody benefits.
Download resources about recombinant antibody development and antibody engineering to boost your research.
Select a product category from the dropdown menu below to view related products.
CAT | Product Name | Application | Type |
---|---|---|---|
MHH-347-F(E) | Recombinant Human Anti-human F9 Antibody Fab Fragment | ELISA, WB, Neut, FuncS | Fab |
HPAB-0345-CN-F(E) | Mouse Anti-F9 Recombinant Antibody; Fab Fragment (HPAB-0345-CN-F(E)) | ELISA, WB | Mouse Fab |
HPAB-0346-CN-F(E) | Mouse Anti-F9 Recombinant Antibody (clone BC2); Fab Fragment | ELISA, Block | Mouse Fab |
HPAB-0347-CN-F(E) | Human Anti-F9 Recombinant Antibody (clone SB249417); Fab Fragment | ELISA, Block | Humanized Fab |
HPAB-0348-CN-F(E) | Human Anti-F9 Recombinant Antibody (clone cBC2); Fab Fragment | ELISA, Block | Human Fab |
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.